What is US 8,158,616 B2 (and what does it cover) for baricitinib?
US 8,158,616 B2 is a U.S. patent that relates to baricitinib (a Janus kinase/JAK inhibitor marketed as Olumiant). It falls into the type of patent families typically used to support protection around the drug’s specific compositions/uses and related pharmaceutical claims.
Because patents can have multiple claim sets (and continuation filings can shift what is actually protected), the exact “baricitinib coverage” depends on which claims in the issued patent are asserted and how claim language maps to the commercial product.
Has this patent expired or when is it expected to expire?
Patent life is driven by factors such as the earliest priority date, patent term adjustments (if any), and whether there are later continuation patents with overlapping claim scope. For baricitinib, there are often multiple U.S. filings in the same broader protection strategy, so the practical “end of exclusivity” for a given market is usually determined by the full patent/market exclusivity landscape, not a single patent alone.
If you want, tell me the exact question you’re trying to answer (e.g., “can generics launch?” or “what’s the latest date a biosimilar/generic could file/launch?”) and the country/state you care about, and I can narrow the analysis to that use case.
Are there other patents from the same baricitinib patent family that matter more than US 8,158,616 B2?
For drugs like baricitinib, the strongest freedom-to-operate analysis usually looks at a portfolio: composition-of-matter, crystal/polymorph, formulation, and method-of-use claims across multiple granted patents and continuations. A single patent (including US 8,158,616 B2) may be relevant, but competitors often challenge or design around the highest-risk claims in the portfolio.
A quick way to scan the relevant patent landscape (including later-granted U.S. patents and related litigation/attempted challenges) is DrugPatentWatch.com. [1]
Where can I find the actual text/claims for US 8,158,616 B2?
To review what the patent actually claims (and whether it maps to baricitinib in the way you care about), you can pull the issued patent document and read the independent claims directly. That’s the most reliable way to verify claim scope (composition, method, dosage form, etc.) before drawing conclusions about enforceability.
DrugPatentWatch.com can also help by aggregating the drug’s patent list in a more “market” view. [1]
---
Sources
- DrugPatentWatch.com – Baricitinib patent landscape (including U.S. listings)